Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review provides a detailed overview of the causes, prevalence, pathophysiology, clinical presentation, and treatment of beard alopecia, highlighting conditions such as alopecia areata, pseudofolliculitis barbae, and tinea barbae, and aims to serve as a resource for clinicians handling such cases.

This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

Injecting triamcinolone into the eyebrow area may help eyelash regrowth in alopecia areata patients.

This study observed that topical prostaglandin treatments may protect against hair follicle injury during chemotherapy, as indicated by preserved eyelashes in patients using these treatments.

This review concluded that topical 5% Minoxidil treatment for androgenetic alopecia yielded the best results and enhancing it with other drugs or procedures further improved outcomes.

In this case study, a 10-year-old girl with infantile ophiastic alopecia areata and ciliary madarosis showed excellent hair and eyelash regrowth after 56 days of treatment involving oral corticosteroids, topical minoxidil, and clobetasol hair lotion, following an initial diagnosis and psychological evaluation.

This study found that topical latanoprost was not effective in treating alopecia areata in eyebrows and eyelashes.

This study found that daily topical application of 500 microg/ml latanoprost led to moderate to marked hair regrowth in a macaque model of androgenetic alopecia.

This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.

In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.

This review found that oral and topical phosphodiesterase inhibitors and topical prostaglandin analogues are safe and effective treatments for various skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia.

This study validated that six out of seven tested topical formulations for alopecia are compatible for 6-month use, suggesting they may be practical for compounding pharmacies.

Latanoprost eye drops caused excessive hair growth and eyelash whitening in a woman.

Latanoprost eye drops caused excessive cheek hair growth and eyelash whitening in a woman.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

New treatments show promise for hair loss, especially JAK inhibitors for alopecia areata.

In this report, a case of steroid-resistant multifocal alopecia areata was successfully treated with topical bimatoprost, suggesting it may be a promising alternative therapy.

Two elderly men developed scalp inflammation after using a gel for skin lesions, which healed with treatment except for some permanent hair loss.

This article presents a case report of a child with coexisting alopecia areata and vitiligo showing improvement with topical prostaglandin E2 treatment, without reporting new clinical results.

This letter to the editor discusses the use of topical cetirizine 1% for treating androgenetic alopecia but reports no new clinical outcomes.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This case report documents a patient experiencing paradoxical depigmentation of the periocular skin after one year of using latanoprost, a finding not previously associated with this medication.

This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.

A woman got a scalp condition from using latanoprost, but it improved after stopping the drug and starting other treatments.

This review summarizes clinical trials and comparative studies showing that latanoprostene bunod 0.024% is effective and safe for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, detailing its mechanism and side effects while considering its therapeutic role.

This study found that topical cetirizine treatment significantly improved hair regrowth and patient satisfaction in male patients with androgenetic alopecia compared to a placebo, highlighting its potential role in treatment.

In this study, a topical lotion containing Redensyl and Sepicontrol A5 demonstrated effectiveness for treating androgenetic alopecia over 24 weeks, with 73.1% of users seeing moderate improvement and notable increases in hair cycle ratios, alongside enhanced quality of life and satisfaction.

This case report describes an 83-year-old man who developed focal neurotoxicity, including paralysis and pain, in the area treated with topical 5-fluorouracil cream for actinic keratoses, suggesting a potential neurotoxic risk associated with the drug, especially in those with a specific genetic deficiency.

This study examined the effectiveness of using intradermotherapy, with or without microneedling and topical solutions, in reducing hair loss among men with androgenetic alopecia, though results are not reported in the abstract.